Academic Journal
Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis
| العنوان: | Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis |
|---|---|
| المؤلفون: | Carrara E., Razzaboni E., Azzini A. M., De Rui M. E., Pinho Guedes M. N., Gorska A., Giannella M., Bussini L., Bartoletti M., Arbizzani F., Palacios-Baena Z. R., Caponcello G., Maldonado N., Rodriguez-Bano J., Visco C., Krampera M., Tacconelli E. |
| المساهمون: | Carrara E., Razzaboni E., Azzini A.M., De Rui M.E., Pinho Guedes M.N., Gorska A., Giannella M., Bussini L., Bartoletti M., Arbizzani F., Palacios-Baena Z.R., Caponcello G., Maldonado N., Rodriguez-Bano J., Visco C., Krampera M., Tacconelli E. |
| سنة النشر: | 2023 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | COVID-19, determinant, hematological malignancie, mortality, severity |
| الوصف: | Main aim of this systematic review is to quantify the risk and identify predictors of clinical evolution of SARS-CoV-2 in hematological patients compared to different control populations. Two independent reviewers screened the literature assessing clinical outcomes of SARS-CoV-2 infection in adult patients with active hematological malignancies published up to June 2021. Primary outcome was COVID-19 related mortality, secondary outcomes were hospital and intensive-care admission, mechanical ventilation (MV), and thromboembolic events. Variables related to study setting, baseline patients' demographic, comorbidities, underlying hematological disease, ongoing chemotherapy, COVID-19 presentation, and treatments were extracted. A total of 67 studies including 10,061 hematological patients and 111,143 controls were included. Most of the studies were retrospective cohorts (51 studies, 76%) and only 19 (13%) provided data for a control group. A significant increased risk of clinical progression in the hematological population compared to the controls was found in terms of COVID-19 related mortality (OR, 2.12; 95% CI, 1.77-2.54), hospitalization (OR, 1.98; 95% CI, 1.15-3.43), intensive-care admission (OR, 1.77; 95% CI, 1.38-2.26), and MV (OR, 2.17; 95% CI, 1.71-2.75). The risk remained significantly higher in the subgroup analysis comparing hematological patients versus solid cancer. Meta-regression analysis of uncontrolled studies showed that older age, male sex, and hypertension were significantly related to worse clinical outcomes of COVID-19 in hematological population. Older age and hypertension were found to be associated also to thromboembolic events. In conclusion, hematological patients have a higher risk of COVID-19 clinical progression compared to both the general population and to patients with solid cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/36238977; info:eu-repo/semantics/altIdentifier/wos/WOS:000870538200001; volume:41; issue:1; firstpage:16; lastpage:25; numberofpages:10; journal:HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA; https://hdl.handle.net/11585/918049; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85140263790 |
| DOI: | 10.1002/hon.3084 |
| الاتاحة: | https://hdl.handle.net/11585/918049 https://doi.org/10.1002/hon.3084 https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3084 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.7F6C819B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/hon.3084 |
|---|